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A B S T R A C T
Purpose
The rare association between breast cancer and pregnancy means that few oncologists gain
an expertise in this area. In particular, there are few published data concerning the use of
chemotherapy for breast cancer during pregnancy. In this retrospective case series, we
describe the experiences of five hospitals in London, United Kingdom, and how they manage
this condition.
Patients and Methods
Retrospective searches were performed at five London hospitals in order to identify women
who received chemotherapy for breast cancer while pregnant.
Results
Twenty-eight women were identified who had received chemotherapy for breast cancer during
pregnancy. Twenty-four women received adjuvant or neoadjuvant chemotherapy for early breast
cancer, and four women received palliative chemotherapy for metastatic disease. A total of 116
cycles of chemotherapywere administered during pregnancy. Sixteenwomenwere treatedwith
anthracycline-based chemotherapy and 12 received cyclophosphamide, methotrexate, and
fluorouracil. All but one of the women were treated after the first trimester. One spontaneous
abortion occurred in the woman treated during her first trimester; otherwise, there were no
serious adverse consequences for the mothers or neonates.
Conclusion
These data provide evidence that in terms of peripartum complications and immediate fetal
outcome, chemotherapy can be safely administered to women during the second and third
trimesters of pregnancy.
J Clin Oncol 23:4192-4197. © 2005 by American Society of Clinical Oncology
INTRODUCTION
It has been estimated from 32 case series
over a period of several decades that 0.2% to
3.8% of breast cancers occur during preg-
nancy.1 This incidence may rise as women
delay their pregnancies until later in life, and
as the number of premenopausal women
with breast cancer grows.2,3 Pregnancy com-
plicates the management of breast cancer
because the need for treatment to maximize
chances of survival for themother have to be
balanced against the potential risks to the
fetus. This is particularly the case when the
use of chemotherapy is proposed in a preg-
nant woman. Adjuvant chemotherapy has a
well-established role in improving survival
for women with early breast cancer.4 Delays
or modification of adjuvant treatment to
ensure the birth of a healthy infant could
potentially compromise maternal survival.
It is therefore important to establish what
treatments are safe for both mother and the
developing fetus during pregnancy. Owing
to the rarity of this association and the infre-
quent use of chemotherapy in pregnancy,
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most existing reports are anecdotal. This retrospective se-
ries is the largest published thus far and documents data
from five hospitals concerning the use of chemotherapy for
breast cancer in pregnant women.
PATIENTS AND METHODS
Patients who had undergone treatmentwith cytotoxic chemother-
apy for breast cancer during pregnancy were identified from a
search of the prospectively maintained Royal Marsden Hospital
(London, United Kingdom) breast unit database. This search cov-
ered the period from 1986 to 2003. Additional cases were sought
based on physician and nursing recall at the Royal Free, Whitting-
ton, Guy’s, and King’s College Hospitals (all institutions, London,
United Kingdom), covering the period from 1990 to 2003. Among
them, these institutions see approximately 1,500 patients with new
diagnoses of breast cancer annually. After ethical approval and
retrospective patient consent (whenever possible) was acquired, a
36-itemquestionnairewas completed directly frompatients’med-
ical records. Details regarding diagnostic and staging investiga-
tions, standard histopathologic parameters, hormone-receptor,
and human epidermal growth factor receptor 2 (HER2) status
were recorded, if available. Patients were classified as having in-
flammatory breast cancer on the basis of clinical findings (diffuse
erythematous indurated skin) or histologic evidence of the inva-
sion of dermal lymphatics. Information was recorded regarding
pre- and postpartum treatments and, in particular, types and
doses of chemotherapy and their toxicities. Obstetric information
documented included gestational age at diagnosis, complications
of pregnancy, labor, and delivery, including fetal complications
and congenital abnormalities.
RESULTS
Baseline Characteristics
Sixty-three women who were pregnant at the time of
diagnosisor relapseofbreast cancerwere identified; 28of these
women went on to receive chemotherapy while pregnant. Of
these 28 women, 24 were diagnosed with stage I-IIIB disease:
stage I (two women), stage II (11 women), and stage III (11
women; staging was done using the American Joint Commit-
tee on Cancer revised staging system for breast cancer5). An
additional four patients were treated for metastatic disease
(stage IV). Of the four patients treated for metastatic disease,
two had stage IV breast cancer at presentation and two had
relapsedwhilepregnant.Themedianmaternal ageatdiagnosis
was33years (range,28 to42years).Themediangestational age
at diagnosis was 17 weeks (range, 4 to 33 weeks). The median
duration of symptoms before histologic confirmation of diag-
nosis was 9 weeks (range, 2 weeks to 12months).
Surgery
Seventeen patients underwent surgery while pregnant;
10 of the 17 patients had modified radical mastectomies,
and seven patients underwent breast-conserving surgery.
Fifteen of the 17 patients underwent axillary surgery. The
median gestational age at the time of surgery was 16 weeks
(range, 5 to 29 weeks). There were no unexpected surgical
or anesthetic complications. Four patients had surgery after
delivery, following primary chemotherapy received while
pregnant. Seven patients did not have surgery; three of these
patients received neoadjuvant chemotherapy alone and
four received palliative chemotherapy for metastatic dis-
ease. All seven of the patients who underwent breast-
conserving surgery and seven of the 10 patients who
underwent mastectomy while pregnant received postpar-
tum radiation therapy.
Histopathology
Histopathologic characteristics of the 24 patients who
presented with stage I to IIIB breast cancer while pregnant
are listed in Table 1. The majority of tumors were invasive
Table 1. Surgical Pathologic Features for Patients Undergoing Treatment
for Stage I-IIIB Breast Cancer During Pregnancy
No. of Patients
(N  24)
Neoadjuvant
Chemotherapy
(n  7)
No Neoadjuvant
Chemotherapy
(n  17)
Tumor size, cm
Mean 6 3.6
Range 1.2-11† 1-10
Lymph nodes involved
None 0 3
1-3 1 7
4-9 1 4
 9 1 1
Not known 4 2
Histologic type
Ductal 19
Lobular 1
Other 2‡
Not known 2
Histologic grade
I 0
II 6
III 17
Not known 1
Lymphovascular invasion
Present 15
Absent 2
Not known 7
Estrogen receptor
Positive 11
Negative 8
Not known 5
HER2 status
Positive 5
Negative 7
Not known 12
Abbreviation: HER2, human epidermal growth factor 2.
Three patients did not undergo surgery following neoadjuvant chemotherapy.
†Postchemotherapy tumor size.
‡Medullary.
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ductal carcinomas (in 86% of patients for whom this
informationwas available). There were also high incidences
of adverse prognostic features, including high tumor grade
(74% of patients), lymphovascular invasion (88% of pa-
tients), and estrogen-receptor (ER) –negative tumors (42%
of patients). Lymph node status was known for 18 patients,
of whom 15 (83%) were node positive. Three of the tumors
also exhibited inflammatory features.
Chemotherapy
Neoadjuvant chemotherapy was initiated during preg-
nancy in seven patients for large operable, locally advanced,
or inflammatory breast cancers. Adjuvant chemotherapy
was administered to 17 patients, and four patients received
palliative chemotherapy for metastatic disease. A total of
116 cycles of chemotherapywere administered during preg-
nancy in this cohort; the median number of cycles admin-
istered prepartum was four (range, one to six). The median
total number of cycles of chemotherapy administered dur-
ing and after pregnancy was six (range, four to eight cycles).
Fourteen of the patients received chemotherapy prepartum
only, whereas the remaining 14 received chemotherapy
both during and after pregnancy. The types and doses of
chemotherapy administered are listed in Table 2. These
chemotherapy regimes were tolerated at full doses without
major complications. Three episodes of febrile neutropenia
were recorded, but all patients responded to antibioticswith
no additional complications. The only other grade 3 or 4
toxicities recorded were lethargy (two patients) and alope-
cia. Two of the patients also received granulocyte colony-
stimulating factor while pregnant. No patients received
endocrine therapy or radiotherapy during pregnancy.
Obstetric Characteristics
Obstetric characteristics related to chemotherapy ad-
ministration are reported in Table 3. The median gesta-
tional age at the commencement of chemotherapy was 20
weeks (range, 15 to 33 weeks). Twenty-two patients started
chemotherapy in the second trimester and five during the
third trimester. One patient received cyclophosphamide,
methotrexate, and fluorouracil (CMF) chemotherapy dur-
ing the first trimester of her pregnancy. She was not aware
that she was pregnant at the time of chemotherapy initia-
tion, but had a positive pregnancy test shortly after the first
cycle. Unfortunately, she had a spontaneous abortion be-
fore her second cycle of treatment. The median interval
between the last cycle of chemotherapy and delivery was 28
days (range, 14 to 70 days). Six patients had cesarean deliv-
eries, and an additional seven patients had their labor in-
duced. The median gestational age at delivery was 37 weeks
(range, 30 to 40 weeks). Nine children were born before 37
weeks’ gestation; one case was as a result of spontaneous
onset of labor. The patient who delivered at 30weeks had an
early elective cesarean delivery owing to impending spinal
cord compression.
Fetal Outcome
The median gestational age at delivery was 37 weeks
(range, 30 to 40weeks).One child had a hemangiomaonhis
abdomen, but it was not thought to be causally related to
chemotherapy exposure. Therewere no other recorded fetal
abnormalities. Birth weight was available for 17 of the in-
fants; the median birth weight was 3.0 kg (1.4 to 3.5 kg). In
the infant born weighing 1.4 kg, placental insufficiency was
identified as the cause of intrauterine growth retardation,
and an elective cesarean delivery was carried out at 32
weeks. However, none of the infants had a birthweight
lower than the 10th percentile for gestational age.6 Two of
the newborns experienced respiratory distress, and in total
five newborns needed to be transferred to neonatal high
dependency units.
Table 2. Chemotherapy
No. of Patients
Adjuvant Neoadjuvant Palliative Total
Doxorubicin and cyclophosphamide 5 4 2 11
Epirubicin and cyclophosphamide† 3 0 2 5
Cyclophosphamide, methotrexate, and fluorouracil‡ 9 3 0 12
Total 17 7 4 28
Abbreviation: iv, intravenously.
Doxorubicin 50-60 mg/m2 iv day 1, cyclophosphamide 600 mg/m2 iv day 1, every 3 weeks.
†Epirubicin 60-100 mg/m2 iv day 1, cyclophosphamide 600 mg/m2 iv day 1, every 3 weeks.
‡Cyclophosphamide 100-150 mg orally days 1-14, methotrexate 40 mg/m2 iv days 1 and 8, fluorouracil 600 mg/m2 iv days 1 and 8; every 4 weeks.
Table 3. Obstetric Characteristics
Characteristic Median Range
Maternal age, years 33 28-42
Gestational age at diagnosis, weeks 17 4-33
Gestational age at surgery, weeks (n 17) 16 5-29
Gestational age at start of chemotherapy, weeks 20 15-33
Interval between delivery and last cycle of
chemotherapy, days
28 40-70
Gestational age at delivery, weeks 37 30-40
Ring et al
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Maternal Outcome
As of October 2003, the median follow-up period for
the women in this report was 40.5 months (range, 7 to 159
months). Two of the women with stage IV disease died
within 3 years of diagnosis, and the other two patients are
both alive at 1 year of follow-up. At a median of 40.5
months, the combined survival rate for women with stage I
to IIIB breast cancer was 67%, and the disease-free survival
rate was 63%.
DISCUSSION
The purpose of conducting this retrospective review was to
provide more information to breast cancer specialists and
obstetricians faced with a pregnant patient with breast can-
cer requiring chemotherapy. We are aware of only two case
series of a similar size: a French national survey7 and a series
from The University of Texas M.D. Anderson Cancer Cen-
ter (Houston, TX).8 The French national survey was a ret-
rospective study based on a postal questionnaire sent to
clinicians involved in the management of breast cancer
diagnosed during pregnancy. Data were acquired on the
histologic and clinical characteristics, treatment, obstetric
complications, and pregnancy outcome of 20 women
treated with chemotherapy for breast cancer while preg-
nant. The M.D. Anderson Cancer Center series was a pro-
spectively designed study where patients with primary or
recurrent breast cancer diagnosed during pregnancy were
managed with locoregional therapy and a standard chemo-
therapy protocol as clinically indicated. The chemotherapy
regimen used was doxorubicin 50 mg/m2 continuous infu-
sion over a period of 72 hours, cyclophosphamide 500
mg/m2 on day 1, and bolus fluorouracil 500mg/m2 on days
1 and 4. In the initial publication, data were presented on 24
women, two of whom had recurrent disease, and one of
whom received chemotherapy during her first trimester.8
An update of this series including 39 patients has also been
presented in abstract form.9
The pathologic characteristics of the tumors treated
were similar to those reported in other series, in that the
majority of tumors were high-grade invasive ductal carcino-
mas.7,10 Twenty-fiveof 28patients in this studypresentedwith
pathologic lymph node involvement or metastatic disease;
similarly Middleton et al10 found that only 2 of 39 patients
presenting with breast cancer during pregnancy had stage I
disease. Patients with breast cancer who are pregnant at the
time of diagnosis have previously been shown to present with
more advanced disease thanmatchednonpregnant patients in
some,11,12 but not all,13 case-control studies. Of the 19women
with stage I to IIIB breast cancer for whom ER status was
available, eight were estrogen-receptor–negative. ER-negative
tumors are known to bemore common in younger women,14
but in case control studies, ER-negative tumors have been
shown to be more frequent in pregnant patients than in age-
matched controls.11,13,15 It has also previously been observed
that breast cancer in patients who are pregnant often demon-
strate lymphovascular invasion, and are relatively frequently
HER2-positive, though whether their frequencies are any dif-
ferent to those in age-matched controls is not known.11,15
The use of cytotoxic drugs during pregnancy is compli-
cated by the potential for teratogenicity as demonstrated in
animal studies, together with the risk of other direct toxic
effects on the mother and fetus. During the first trimester,
the fetus is undergoing organogenesis, and therefore is at its
most susceptible. Chemotherapy at this stage may be asso-
ciated with spontaneous abortions or an increased risk of
fetal malformations.16 One of the patients in this series, and
two patients in the French national survey were exposed to
chemotherapy during the first trimester, and all underwent
spontaneous abortions.7 However, the one patient exposed
to chemotherapy during the first trimester (11weeks) in the
M.D. Anderson series experienced no apparent adverse ef-
fects.8 When live births do occur, historical studies suggest
that fetal malformation rates are between 7.5% and
17%.17-20 Because of the high rates of pregnancy loss and
fetal malformations, chemotherapy is generally avoided
during the first trimester.
Beyond the first trimester, the use of cytotoxic chemo-
therapy does not appear to increase the risk of malforma-
tions. In this series, none of the 27 children exposed to
chemotherapy in the second or third trimesters had con-
genital malformations. Sixteen of these children had been
exposed to anthracyline-based chemotherapy. In the M.D.
Anderson series, 23 children were exposed to anthracyline-
based chemotherapy in the second and third trimesters
(doxorubicin, cyclophosphamide, and fluorouracil at the
doses previously described) and similarly nomalformations
were reported.8 Our series also included 12 patients who
received CMF chemotherapy. In the first trimester, metho-
trexate is particularly associated with birth defects, but we
can find no evidence of such an effect later in pregnancy.
The French national survey identified 18 patients who re-
ceived a variety of chemotherapy regimes during the second
and third trimesters of pregnancy, and no fetal malforma-
tions were identified.7 Four of these patients received vi-
norelbine, which has previously been administered with no
fetal complications.21 Case reports also describe the use of
docetaxel and paclitaxel in the second and third trimesters
respectively, with no adverse effects.22,23 There is no evi-
dence from animal studies that granulocyte colony-
stimulating factor is teratogenic, and there are reports of its
use during pregnancy (Medical Information Department,
personal communication, April 2003).24 Two patients in
the current series also received granulocyte colony-
stimulating factor with no significant adverse effects.
The toxic effects of cytotoxic agents are not restricted
to fears over teratogenicity. Pre-eclampsia, preterm labor,
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intrauterine death, and low birth weights have all been
reported in previous series.7,8,20,25 However, it is not known
whether the incidences of these complications are in excess
of those in the normal population and what the contribu-
tion of chemotherapy is relative to the effects of the under-
lying disease. Nine of the children were delivered before 37
weeks, and in one case premature delivery occurred as a
result of spontaneous onset of preterm labor. In the remain-
der, early delivery was explained by induced labor or cesarean
delivery in order to optimize the timing of delivery relative to
chemotherapy, or, in one case, to allow treatment of spinal
cord compression. Intrauterine growth retardation is likely to
be underestimated in retrospective studies, though one case
each was identified in the French national survey and the
current study. Of the 17 babies in this series for whom birth
weights were available, two had low birth weights ( 2.5 kg).
Increased neonatal morbidity and mortality are recognized
sequelae of intrauterine growth retardation and low birth
weight ( 2.5 kg) in the normal neonatal population.26 How-
ever, noneof the infants in this series andonlyone infant in the
M.D. Anderson series had a birth weight lower than the 10th
percentile for gestational age.8
Maternal and neonatal sepsis and hemorrhage are po-
tential complications ofmyelosuppression, which can effect
both mother and fetus at the time of delivery.7,8,27,28 No
such complications were observed in this cohort, though
the mean interval between delivery and the last cycle of
chemotherapy was 30 days, minimizing the risk of neutro-
penia at the time of delivery.
The potential long-term effects of exposing the fetus to
chemotherapy include gonadal dysfunction, impaired
physical and neurologic development, and germ cell mu-
tagenesis resulting in carcinogenesis and teratogenicity in
subsequent generations.29 However, follow-up of children
is often short and reports concerning long-term develop-
ment are uncommon. The most comprehensive cohort to
date describes 84 children born to mothers who were
treated with combination chemotherapy during pregnancy
for hematologic malignancies.30 At a median follow-up of
18.7 years, normal physical, neurologic, and psychological
developmentwas observed, with no reports ofmalignancies
in the 84 first-generation children or in the 12 second-
generation children.
Given that some transplacental transfer of anthracyclines
may occur, fetal cardiotoxicity followingmaternal exposure to
anthracyclines is another long-term concern.31,32 No cases of
fetal cardiotoxicity were recorded in one large review33-35 of
the use of anthracyclines in pregnancy, and no echocardio-
graphic changeswere observedwhen a childwasmonitored in
utero. Unfortunately, this case series and many others on this
topic are unable to adequately address such late adverse effects
owing toa lackof long-termfollow-upand thebias introduced
by their retrospective nature. For these reasons, the ongoing
analysis of theM.D. Anderson data and new prospective data-
bases such as that initiated by theGermanBreast Group are of
utmost importance.36
The data presented in this series provide evidence that
in consideration of peripartum complications and immedi-
ate fetal outcome, chemotherapy can be safely administered
to women during the second and third trimesters of preg-
nancy. The literature reviewed also indicates that there are
unlikely to be serious adverse long-term effects on the fetus,
though large prospective series are needed to confirm this.
Nonetheless, on the basis of the current evidence women
should not be denied the potential benefits of chemother-
apy because they are pregnant at the time of diagnosis of
breast cancer.
■ ■ ■
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